BIOMUNEX strategy is to develop its proprietary disruptive programs and establish partnerships and collaborations with pharmaceutical and biopharmaceutical companies interested in its proprietary BiXAb innovative technologies and/or antibodies currently developed, such as MAIT engagers.

BIOMUNEX is focused on establishing deals based on the BiXAb® technologies, that may bring revenues, thanks to collaborations and out-licensing deals with major pharmaceutical and biopharma companies, such as the Sanofi deal or the global licensing agreement signed with Ipsen. Expected revenue streams would enable high-level upfronts, clinical, regulatory, and comerciallization milestones, royalties and additional payments, enabling the further development of the company’s pipeline and innovative technology.